HOXB2 as a Novel Prognostic Indicator for Stage I Lung Adenocarcinomas  by Inamura, Kentaro et al.
ORIGINAL ARTICLE
HOXB2 as a Novel Prognostic Indicator for Stage I Lung
Adenocarcinomas
Kentaro Inamura, MD, PhD,* Yuki Togashi, MPharm,* Michiyo Okui, PhD,*
Hironori Ninomiya, MD,* Miyako Hiramatsu, MD,* Yukitoshi Satoh, MD, PhD,*‡
Sakae Okumura, MD,‡ Ken Nakagawa, MD,‡ Takashi Shimoji, MD, PhD,†
Tetsuo Noda, MD, PhD,† and Yuichi Ishikawa, MD, PhD*
Background: Outcomes of patients with lung adenocarcinomas can
be predicted to some extent from the pathologic stage (p-stage).
Although all attempts are made to fully remove cancer lesions, still
a number of p-stage I patients without metastatic disease at the time
of surgery develop recurrences and die of cancer. It is thus very
important to identify p-stage I patients who are at risk of recurrence.
Methods: Previously, using microdissected samples, we identified
metastasis-related genes. Using real-time reverse-transcriptase poly-
merase chain reaction analysis, we investigated the transcriptional
levels of the top metastasis-related genes using 96 independent test
lung adenocarcinoma samples and investigated their correlations
with the prognosis.
Results and Conclusions: We document evidence that p-stage I
patients with HOXB2 up-regulation have a worse prognosis than
those with HOXB2 down-regulation (p  0.0065), whereas the
HOXB2 status has no prognostic significance for p-stage II–IV
patients. Comparing tumors and corresponding normal lung tissue,
we confirmed HOXB2 up-regulated lesions to have much higher
HOXB2 expression than the corresponding normal tissue. Confir-
mation with a larger number of samples is needed, with further
research to clarify the molecular functions of HOXB2.
Key Words: Lung adenocarcinoma, HOXB2, Real-time RT-PCR,
Prognostic indicator.
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Lung cancer is the leading cause of cancer death in men andwomen worldwide and adenocarcinoma is the most pre-
dominant histologic subtype in many parts of the world.
Clinical outcomes can be roughly predicted by pathologic
stage (p-stage). Five-year survival for p-stage I cases, patho-
logically lacking metastases, is relatively good, ranging from
60%1 to 90%.2 Even when cancer lesions have been fully
removed and no metastasis was found at surgery, however,
some patients with p-stage I suffer recurrence and die of the
cancer relapse. Presumably, these had micrometastasis at the
time of surgery.
It is clearly important to identify p-stage I patients who
have the risk of recurrence and using the laser capture
microdissection (LCM) technique, we previously examined
genome-wide expression profiles of lung adenocarcinomas.3
After showing the striking similarities of gene expression
between primary lung adenocarcinomas and their metastatic
lesions, we could identify a 75-gene signature differentially
expressed between lymph node–positive and -negative pri-
mary lung adenocarcinomas. These metastasis-related 75
genes comprise 37 with significantly higher expression in
node-positive than node-negative primary tumors and 38 with
significantly lower expression. Furthermore, we showed that
this metastasis-related gene expression signature was preva-
lent in entire primary lesions, including the morphologically
less malignant components. We therefore focused on identi-
fication of prognostic markers in macrodissected samples, or
bulk tumors, instead of microdissected tissue because LCM
clinical examinations are practically impossible.
In this study, we investigated transcriptional levels of
the top metastasis-related genes that we previously found,
with the goal of detecting a candidate gene whose expression
level might be a prognostic indicator for p-stage I patients.
Herein, we found evidence that p-stage I patients with
HOXB2 up-regulation have a worse prognosis than those
with HOXB2 down-regulation. HOXB2 is one of the 39
HOX genes in humans that encode the transcription factors
and act as master regulators of the morphogenesis and cell
differentiation.4
METHODS
Clinical Samples and RNA Extraction
For screening of top metastasis-related genes by LCM,
19 macrodissected primary lung adenocarcinoma cases were
examined for differential expression between nine node-
positive and 10 node-negative samples.3 For the present test
samples, 96 primary lung adenocarcinomas independent of
those previously examined to identify the metastatic signature
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were used. For comparison between carcinoma and normal
components, we included 19 corresponding normal lung
tissue samples. In addition, we included 20 normal lung
samples from patients undergoing surgery for metastatic
cancers. For 12 samples that we examined previously using
the LCM technique, we compared the expression levels
between microdissected and macrodissected samples. All
clinical samples were collected with ethical committee ap-
proval and informed consent from patients undergoing sur-
gery at the Cancer Institute Hospital, Tokyo, Japan, between
March 1997 and May 2002. All were grossly dissected and
snap-frozen in liquid nitrogen within 20 minutes of removal
and stored at 80°C until RNA extraction. For LCM, the
Application Solutions Laser Microdissection System (Leica
Microsystems, Wetzlar, Germany) was used. The reference
sample was a mixture of normal lung clinical samples, lung
cancer clinical samples, and lung cancer cell lines (MS-1,
SQ-5, and NCI-H522). Total RNA was extracted and purified
using an RNeasy Mini Kit (QIAGEN, Valencia, CA). RNA
quality and absence of genomic DNA contamination were
checked by formaldehyde agarose gel electrophoresis.
Real-time Reverse-Transcriptase Polymerase
Chain Reaction (RT-PCR) Analysis
Real-time RT-PCR analysis was performed using an ABI
7300 sequence detection system (Applied Biosystems, Foster
City, CA) and TaqMan Gene Expression Assays (Applied Bio-
systems) according to the manufacturer’s instructions. Assay
IDs for each gene were as follows: HOXB2 (assay
ID: Hs00609873_g1), NGEF (assay ID: Hs00294813_m1),
MAGED1 (assay ID: Hs00199603_m1), SFRS11 (assay ID:
Hs00191108_m1), VAPA (assay ID: Hs00427749_m1), ZFP36
(assay ID: Hs00185658_m1), and IQGAP1 (assay ID:
Hs00182622_m1). For the seven genes, nine lymph node-posi-
tive and 10 node-negative lung adenocarcinomas that were
previously examined using microdissected samples were com-
pared using macrodissected samples by t test. For HOXB2,
SFRS11, and IQGAP1, the 96 test adenocarcinoma samples
were also examined, along with 20 normal lung samples for
HOXB2 20 and six for SFRS11 and IQGAP1. TaqMan -actin
Pre-Developed Reagent (Applied Biosystems) was used for
normalization and the expression levels of each gene were
assessed relative to the reference sample expression. PCRs for
each gene were performed in triplicate and averaged. PCR
cycles were as follows: 2 minutes at 50°C, 10 minutes at 95°C,
and 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.
Semiquantitative RT-PCR Analysis
Total RNAs were reverse transcribed with the oli-
go(dT)12–18 primer and SuperScript III reverse transcriptase
(Invitrogen, Carlsbad, CA). Semiquantitative RT-PCR exper-
iments were carried out with synthesized HOXB2 gene-
specific primers (5=-TCCACCCTTCAGAGACCCA-3= and
5=-GCGGGTGACAGCAGGCTT-3=) (566 bp), or with -ac-
tin (ACTB)-specific primers (5=-CCCAGCACAATGAA-
GATCAAGATCAT-3= and 5=-ATCTGCTGGAAGGTGGA-
CAGCGA-3=) (101 bp) as an internal control. For PCR of
HOXB2, after initial denaturation at 94°C for 2 minutes, 29
cycles, each consisting of denaturation at 94°C for 15 sec-
onds, annealing at 60°C for 30 seconds, and strand elongation
at 68°C for 1 minute, were performed, followed by a final
elongation at 68°C for 10 minutes. For ACTB, amplification
was performed for 25 cycles with denaturation for 15 seconds
at 94°C, primer annealing for 30 seconds at 58°C, and
elongation for 30 seconds at 68°C. PCR was performed using
KOD-Plus Version 2. DNA polymerase (TOYOBO, Osaka,
Japan) and 0.5 M betaine (Sigma, St. Louis, MO) were added
to the PCR reaction mixture to improve efficiency.
Analysis of Clinicopathologic Parameters
Cumulative survival rates were calculated by means of
the Kaplan-Meier method and compared by the log-rank test
using disease-specific survival data. We analyzed statistical
correlations for the other clinicopathologic features using the
Student’s t test or 2 test as appropriate. The two-sided
significance level was set at p  0.05.
RESULTS
At first, we used macrodissected samples and screened
for transcription levels of the top three up-regulated genes
(HOXB2, NEGF, and MAGED1), the top three down-regu-
lated genes (SFRS11, VAPA, and ZFP36), and IQGAP1, one
of the metastasis-related markers identified by another mi-
croarray study.5 Although HOXB2 (p  0.012) and IQGAP1
(p  0.0094) demonstrated statistically significant variation
in expression between node-positive and node-negative sam-
ples, there were no significant differences for NEGF (p 
0.49), MAGED1 (p  0.97), SFRS11 (p  0.13), VAPA
(p  0.061), and ZFP36 (p  0.71).
Using the 96 independent test lung adenocarcinoma
samples, we examined the transcription levels of HOXB2 and
IQGAP1 as well as SFRS11 and generated Kaplan-Meier
survival curves with the log-rank test statistical analysis
(Figure 1A). Although for IQGAP1 (p  0.62) and SFRS11
(p 0.66), there were no prognostic differences between two
groups with greater or lower than average control transcrip-
tional levels, a tendency for differences in survival was
observed for HOXB2 (p  0.11).
We then separated the 96 test samples into p-stage I and
p-stages II–IV and again generated Kaplan-Meier survival
curves (Figure 1B). Of note, survival for p-stage I patients
was significantly different between the two groups divided by
HOXB2 expression (p  0.0065), whereas there was no
prognostic difference for p-stage II–IV patients (p  0.91).
To confirm that HOXB2 was up-regulated relative to
the corresponding normal lung tissue, we examined transcrip-
tion in 19 cases, 10 with HOXB2 down-regulation and nine
with up-regulation. Ratios of tumors to normal tissues were
significantly elevated in HOXB2 up-regulated cases (21.7 
13.9) than in HOXB2 down-regulated cases (1.4  0.8) (p 
0.0069). The average and SD of the 39 normal lung tissues
was 0.59  0.28. HOXB2 expressions of 19 normal lung
tissues from lung cancer patients were slightly lower than
those of 20 from metastatic cancer patients (0.45  0.19
versus 0.71  0.29).
To confirm the efficacy of using macrodissected sam-
ples, we compared HOXB2 transcriptional levels with those
in 12 microdissected lung adenocarcinoma samples. In mi-
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crodissected samples, only cancer cells were isolated,
whereas in macrodissected samples, cancer cells and sur-
rounding noncancerous interstitial tissues were included.
HOXB2 transcriptional levels detected by real-time RT-PCR
showed a highly significant correlation between values for
microdissected and macrodissected samples (Figure 2; r 
0.86, p  0.00028).
When tumors and corresponding normal lung tissues
from three HOXB2 up-regulated and three down-regulated
cases were examined by semiquantitative RT-PCR for
HOXB2 with the longer amplification products (566 bp)
(Figure 3), only the up-regulated cases showed elevated
HOXB2 expression in the tumors. There were no significant
correlations for any other clinicopathologic parameters in-
FIGURE 1. (A) Kaplan-Meier survival curves with reference to transcriptional levels for HOXB2, IQGAP1, and SFRS11. p Values
were obtained by log-rank test. Samples were divided into two groups by the average transcriptional levels of 20 normal sam-
ples for HOXB2 and six for IQGAP1 and SFRS11. (B ) Kaplan-Meier survival curves for cases with reference to transcriptional
levels for HOXB2. p Values were obtained by log-rank test. Samples were divided into two groups by the average transcrip-
tional levels of 20 normal samples for HOXB2. (A) p-stage I (n  52). (B ) p-stages II–IV (n  44).
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cluding tumor stage between the HOXB2 up-regulated and
down-regulated groups (Table 1).
DISCUSSION
The concept of oncogenesis as a multistep process
through accumulated genetic mutations in the development of
an invasive phenotype has been shown in various cancers.
Although precise steps involved in the pathogenesis of lung
adenocarcinoma have not yet been determined, some studies
have analyzed the contribution of different oncogenes and
tumor-suppressor genes to its oncogenesis. The progression
from BAC to invasive adenocarcinoma has been precisely
reviewed in some articles.6–8 Aberrant expression of p53,
Ki67, K-ras, Survivin, Her-2 Neu, FHIT, and other markers
are accumulated along the spectrum of BAC progression to
invasive cancer.6
Prognostic factors for lung adenocarcinomas are des-
perately needed and have been searched for and precisely
reviewed.9,10 For stage I NSCLC, D’Amico et al.11 found
five prognostic markers (p53, factor VIII, erb-b2, CD-44,
and rb) and Soria et al.12 found that overexpression of
cyclin B1 is an adverse prognostic factor. More recently,
by gene expression profiling, Potti et al.13 identified a lung
metagene model that could identify individuals at in-
creased risk of disease recurrence with stage IA NSCLC.
They are planning to use their lung metagene model for a
prospective, randomized clinical trial. Although many
prognostic factors have been found retrospectively, most
of them are never prospectively validated. In future, pro-
spective validations of retrospectively found markers
should be promoted.
In the present study of 96 independent test samples, we
found that HOXB2 may be a novel prognostic indicator for
stage I lung adenocarcinomas that normally have a relatively
good prognosis. Building on our earlier finding that the
metastatic gene expression signature is apparent throughout
the entirety of primary tumors, including the morphologically
less malignant components, we further showed that macro-
dissected, rather than only microdissected, clinical samples
are appropriate for assessment of HOXB2 expression, which
is an adverse prognostic indicator.
P-stage I patients with cancers having metastatic po-
tential are clearly at risk of recurrence and therefore need
additional therapies. Use of HOXB2 up-regulated expression
for their identification is therefore advisable. P-stage II–IV
patients by definition have metastases and thus HOXB2
expression would not be expected to serve as a good prog-
nostic indicator.
FIGURE 2. Correlation diagram between microdissected and
macrodissected samples for HOXB2 expression. An approxi-
mated line is drawn. r, Pearson’s r correlation coefficient.
FIGURE 3. Semiquantitative reverse-transcriptase polymer-
ase chain reaction for HOXB2 (566 bp). Three HOXB2 up-
regulated cases and three down-regulated cases were exam-
ined for pairs of tumor and corresponding normal lung
tissue. Pairs 1, 2, and 3 are HOXB2 up-regulated cases and
pairs 4, 5, and 6 are down-regulated cases. Only in HOXB2
up-regulated cases, tumors showed high HOXB2 expression,
whereas in the other tumors and normal lung samples, only
low HOXB2 expression was evident. -Actin expression is
shown as an internal control.
TABLE 1. Relationship between HOXB2 Transcriptional
Levels and Clinicopathologic Features
HOXB2 Expression
Variables
No. (%) of
Samples
Up-Regulated
(n  30)
Down-Regulated
(n  66) p
Age, yr,
mean  SD
96 65.1  8.3 62.2  9.2 0.14a
Sex 0.38b
Male 61 (64%) 21 (70%) 40 (61%)
Female 35 (36%) 9 (30%) 26 (39%)
Smoking habitc 0.53b
Never 36 (38%) 10 (33%) 26 (40%)
Smoker 59 (62%) 20 (67%) 39 (60%)
Tumor size, mm 0.32b
30 52 (54%) 14 (52%) 38 (58%)
30 44 (46%) 16 (48%) 28 (42%)
Differentiation 0.78b
Well 30 (31%) 9 (30%) 21 (32%)
Moderate 29 (30%) 10 (33%) 19 (29%)
Poor 37 (39%) 11 (37%) 26 (39%)
p-stage 0.58b
I 52 (54%) 15 (50%) 37 (56%)
II–IV 44 (46%) 15 (50%) 29 (44%)
a Student’s t test.
b Chi-square test.
c Smoking habit of one patient was not available.
Journal of Thoracic Oncology • Volume 2, Number 9, September 2007 HOXB2 as a Prognostic Indicator for Lung Cancers
Copyright © 2007 by the International Association for the Study of Lung Cancer 805
HOX genes are a family of regulatory genes containing
a common 183-nucleotide sequence (homeobox) and coding
for specific nuclear proteins that act as transcription factors.14
In the human, there are 39 HOX genes arranged in four
clusters, HOXA, HOXB, HOXC, and HOXD, localized on
chromosomes 7, 17, 12, and 2, respectively.15 Within each
cluster, HOX genes located at the 3= extremity are activated
first and in anterior embryonic domains, whereas 5= located
genes are transcribed subsequently and in more caudal areas,
with precise spatiotemporal regulation.16 HOX genes are also
expressed in some normal adult organs in characteristic
patterns, suggesting possible roles in the maintenance of
tissue-specific architecture in addition to embryogenesis.17 In
the normal human adult lung, HOX genes are predominantly
expressed from the 3= end of clusters A and B, and among
them, HOXA5, HOXB2, and HOXB6 are the most abun-
dant.18 In the current study, we examined 39 normal lung
tissues in total and consistently could detect HOXB2 expres-
sion. In HOXB2 up-regulated cases, tumors showed much
higher HOXB2 expression than the corresponding normal
lung tissues, whereas in down-regulated cases, the differences
were minor.
Aberrant expression of HOX genes has been impli-
cated in leukemias19 and various solid cancers including
renal,20 colon,21 ovarian,22 mammary,23 and pulmonary
carcinomas.24 Lechner et al.25 reported that some HOX
genes of which expression was restricted to pulmonary
embryogenesis were re-expressed in lung cancer cells.
Overexpression of HOXD3 is known to induce coordinated
expression of metastasis-related genes in lung cancer
cells.24 A recent study revealed ectopic HOXB2 expression
in pancreatic cancers and some proportion of its precursor
lesions, pancreatic intraepithelial neoplasias, possibly as-
sociated with a poor prognosis.26 They identified aberrant
expression of several components of the retinoic acid
signaling pathway including HOXB2 and supposed that
overexpression of HOXB2 would be a consequence of
aberrant retinoic acid signaling. In a previous study, we
observed HOXB2 overexpression not only in the central
but also in the peripheral zone of the node-positive primary
tumors. Malignant potential associated with HOXB2 ex-
pression might be acquired early in tumorigenesis.
In conclusion, we found a novel prognostic indicator,
HOXB2, that can separate p-stage I patients with lung
adenocarcinomas into two groups with different prog-
noses. From our results, real-time RT-PCR screening of
macrodissected samples may therefore be recommended.
However, further confirmation with a greater number of
samples and further research to clarify the molecular
functions of HOXB2 are still needed. We are now inves-
tigating the molecular functions of HOXB2 by invasion
assays and microarray analysis.
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